The present study examined the left ventricular wall thickness (LVWT), total urinary kallikrein, total plasma kininogen and mean arterial blood pressure (MABP) in diabetic and non-diabetic Wistar Kyoto (WKY) rats. The MABP was significantly raised (P<0.01) in diabetic WKY rats compared to the respective controls. The LVWT was also significantly (P<0.01) increased in diabetic WKY rats than that of control WKY rats. The mean total urinary kallikrein level and the mean total plasma kininogen level were higher (P<0.01) in diabetic WKY rats, when these rats were treated with captopril (40 mg/kg and 80 mg/kg) against the mean value obtained from control WKY rats. In conclusion, this investigation suggests that diabetes induced in these rats can cause hypertension, increased LVWT and changes in the BK-forming components. Captopril treatment caused reduction in MABP, regression of LVWT and alterations in bradykinin (BK)-forming components. The possible significance of these observations is discussed.
Leeb-LundbergLMFMarceauFMuller-EsterlWPettiboneDJZurawBL. International Union of Pharmacology. XLV. Classification of the kinin receptor family: From molecular mechanisms to pathophysiological consequences. Pharmacol Rev2005; 57:27–77.
2.
KatoriMMajimaM. A missing link between a high salt intake and blood pressure increase. J Pharmacol Sci2006; 100:370–90.
3.
LinzWWiemerGScholkensBA. Cardioprotective actions of bradykinin in myocardial ischemia and left ventricular hypertrophy. Braz J Med Biol Res1994; 8:1949–54.
4.
SharmaJN. Activation of the bradykinin system by angiotensin converting enzyme inhibitors. Eur J Inflammation2010; 8:55–61.
5.
SharmaJNUmaK. Cardiac kallikrein in hypertensive and normotensive rats with and without diabetes. Immunopharmacol1996; 33:341–43.
6.
WangCChaoLChaoJ. Human tissue kallikrein induces hypotension in transgenic mice. Hypertension1994; 23:236–43.
7.
EpsteinMSowersJR. Diabetes mellitus and hypertension. Hypertension1992; 19:403–18.
8.
LiuYJNakagawaYToyaKWangYSaegusaHNakanishiTOhzekiT. Effects of spironolactone on systolic blood pressure in experimental diabetic rats. Kidney International2000; 57:2064–71.
9.
HayashiMNagasakaT. Suppression of norepinephrine-induced thermogenesis in brown adipose tissue by fasting. Am J Physiol1983; 245:E582–6.
10.
AnversaPOlivettiGMelisaariMLoudAV. Morphometric study of myocardial hypertrophy induced by abdominal aortic stenosis. Lab Invest1979; 40:341–8.
11.
SharmaJNKesavaraoU. Effect of captopril on urinary kallikrein, blood pressure and myocardial hypertrophy in diabetic spontaneously hypertensive rats. Pharmacology2002; 64:196–200.
12.
SharmaJNUmaKYusofAP. Altered cardiac tissue and plasma kininogen levels in hypertensive and diabetic rats. Immunopharmacol1999; 43:129–32.
13.
KawashimaHIgarashiTNakajimaYAkiyamaYUsukiKOhtakeS. Chronic hypertension induced by streptozotocin in rats. Arch Pharmacol1979; 305: 123–26.
14.
PellufoVCostaMAPrendesMGMCatanzamOL. Renal alteration and development of hypertension in diabetic rats. Agents actions1992; 38(S):50–57.
15.
SomaniPSinghHPSainiPKRabinovichA. Streptozotocin induced diabetes in the spontaneously hypertensive rats. Metabolism1979; 28:1075–77.
16.
SilberbauerKStanekBTempleH. Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition. Br J Clin Pharmacol1982; 14:87S–93S.
17.
SharmaJNFernandezPGKimBK. Cardiac regression and blood pressure control in Dahl rats treated with enalapril maleate (MK 421), an angiotensin converting enzyme inhibitor. J Hypertension1983; 1:251–6.
18.
SharmaJNStewartJMMohsinSJKatoriMVavrekR. Influence of a kinin antagonist on acute hypotension responses induced by bradykinin and captopril in spontaneously hypertensive rats. Agents Actions1992; 38(S):258–69.
19.
TrippodoNCFrohlichED. The genetically hypertensive rat as a model of human essential hypertension. Circ Res1981; 48: 309–19.
20.
SharmaJNUmaKYusofAPM. Left ventricular hypertrophy and its relation to cardiac kinin-forming system in hypertensive and diabetic rats. Int J Cardiol1998; 63:229–35.
21.
LinzWWiemerGScholkensBA. Bradykinin prevents left ventricular hypertrophy in rats. J Hypertens1993; 11(S):96–97.
22.
AderJLPollackDMButterfieldMIArendshortWJ. Abnormalities in kallikrein excretion in spontaneously hypertensive rats. Am J Physiol1985; 248: F396–F403.
MajimaMKatoriMHanazukaM. Suppression of rat deoxycorticosterone-salt hypertension by kallikrein-kinin system. Hypertension1991; 17:806–13.
25.
ChaoJChaoL. Kallikrein gene therapy in hypertension, cardiovascular and renal diseases. Gen Ther Mol Biol1998; 1:301–8.
26.
OverlackAStumpeKOKollockRResselCKrueckF. Antihypertensive effect of orally administered glandular kallikrein in essential hypertension. Hypertension1981; 3:118–21.
27.
SenSTaraziRCBumpusFM. Cardiac hypertrophy and antihypertensive therapy. Cardiovasc Res1977; 11:427–33.
28.
DahlofBPennertKHansonL. Reversal of left ventricular hypertrophy in hypertensive patients: A meta analysis of 109 treated studies. Am J Hypertension1992; 5:95–110.
29.
SharmaJNKesavaraoU. Changes in plasma prekallikrein activity, blood pressure and left ventricular thickness in hypertensive and normotensive diabetic rats. Methods Find Exp Clin Pharmacol2007; 29:75–8.
